Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035667 · ClinicalTrials.gov registry record
Patient Considerations of Social Media Account Management After Death
A clinical trial of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 117
- Enrollment target
- 1
- Study location
NCT05035667: Active study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT05035667 is a study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 117 participants, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05035667, a study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. Collecting information on the use of social media and preferences will allow for a better understanding of patient's needs in the dying process and may identify populations in need of education, identify a possible source of anxiety and stress, and allow for an informed discussion of digital legacy.
Primary Outcome
Will be measured by Question 10 in the survey: "I have had conversations with my family or friends regarding how I would like any of my social media accounts managed after death", which contains five options: Strongly Disagree, Disagree, Neither Agree or Disagree, Agree, or Strongly Agree. The results will be dichotomized into either "Strongly Agree/Agree" or "Neither Agree or Disagree/ Disagree/Strongly Disagree". A two-sided 95% confidence interval will extend a maximum of 0.063 from the propo
Conditions Studied
Interventions
- OTHER Questionnaire Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT05035667 still lists
NCT05035667 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (34% lower).
The record links to 2 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire Administration is the first listed.
NCT05035667 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05035667 about?
NCT05035667 is a clinical study titled "Patient Considerations of Social Media Account Management After Death". This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death. Collecting information on the use of social media and preferences will allow for a better understanding of pati...
What is the current status of trial NCT05035667?
This trial is currently active not recruiting. The enrollment target is 117 participants. The study started on 2020-12-22. Estimated completion is 2026-12-31.
What conditions does trial NCT05035667 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm.
What interventions are being tested in trial NCT05035667?
The interventions under investigation include: Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05035667?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05035667 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05035667's enrollment target sits among peer trials
117 19th of 108 higher than 90 of 108 other Advanced Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
RECRUITING · NA
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI